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TH-induced cardiac hypertrophy in vivo is accompanied by increased cardiac Transforming Growth Factor-β1( T G F - β1) levels,
which is mediated by Angiotensin II type 1 receptors (AT1R) and type 2 receptors (AT2R). However, the possible involvement of
this factor in TH-induced cardiac hypertrophy is unknown. In this study we evaluated whether TH is able to modulate TGF-β1i n
isolated cardiac, as well as the possible contribution of AT1R and AT2R in this response. The cardiac ﬁbroblasts treated with T3 did
not show alteration on TGF-β1 expression. However, cardiomyocytes treated with T3 presented an increase in TGF-β1 expression,
as well as an increase in protein synthesis. The AT1R blockade prevented the T3-induced cardiomyocyte hypertrophy, while the
AT2R blockage attenuated this response. The T3-induced increase on TGF-β1 expression in cardiomyocytes was not changed by
the use of AT1R and AT2R blockers. These results indicate that Angiotensin II receptors are not implicated in T3-induced increase
on TGF-β expressionandsuggestthatthetrophiceﬀectsexertedbyT3 oncardiomyocytes arenotdependentonthehigherTGF-β1
levels, since the AT1R and AT2R blockers were able to attenuate the T3-induced cardiomyocyte hypertrophy but were not able to
attenuate the increase on TGF-β1l e v e l sp r o m o t e db yT 3.
1.Introduction
The major causes of morbidity and mortality in Western
societies have been associated with cardiac hypertrophy and
heart failure, which are inﬂuenced by several factors [1,
2]. In this context, the cardiomyocytes are known to play
important role in the adaptation of myocardial structure and
function during cardiac hypertrophy [3–6]. In this sense,
several studies have investigated the eﬀects promoted by
hypertrophic stimulus in isolated cardiomyocytes in order
to evaluate the complex process that coordinates the cardiac
hypertrophy.
Increased thyroid hormone (TH) levels exert important
eﬀects on the cardiovascular system, including the induction
of cardiac hypertrophy. TH metabolic disarray, as occurs in
the hyperthyroidism, has been identiﬁed as a high-risk factor
for the progression of cardiac diseases and development of
heartfailure[7].Inaddition,THhasbeenshowntostimulate
growth in cardiomyocytes in vitro and in vivo, through a
combination of direct and indirect eﬀects, which lead to
increased cell size, protein synthesis, and changes in target
genes related to cardiac function [8]. In the last decade, some
studies demonstrated that the Renin Angiotensin System
(RAS) exerts a critical role to the development of the TH-
inducedcardiachypertrophyinvivo[9,10]andinvitro[11].
The Angiotensin II (Ang II), one of the main eﬀectors of the
RAS, exerts its eﬀects via the Ang II type 1 (AT1R) and type
2 receptors (AT2R). Although most of hypertrophic eﬀects
of Ang II are mediated by the AT1R [12], the AT2R has also
been implicated in mediating cardiac growth [13, 14].
Another important mediator of the cardiac hypertrophy
is the Transforming Growth Factor-β1( T G F - β1) [15, 16],2 International Journal of Endocrinology
which is present in cardiomyocytes and has been implicated
in promoting growth of these cells [17]. In this sense,
stimulus that triggers the expression of TGF-β1h a sb e e n
associated with an increase on the Ang II levels in the
cardiac tissue [18]. Our group recently demonstrated that
TH-inducedcardiachypertrophyisaccompaniedbyelevated
Ang II levels in vivo and in vitro [11]. Moreover, we also
showed that TH-induced cardiac hypertrophy in vivo is
accompanied by an increase of cardiac TGF-β1 expression,
which occurs in dependence on AT1R and AT2R activation
[19]. However, the possible contribution of this factor to
the TH-induced cardiac hypertrophy is not known. In the
same way, the possible involvement of the higher Ang II
levels to the TGF-β1 modulation induced by T3 in isolated
cardiaccells,aswellasthepossiblecontributionofAT1Rand
AT2Rinthisresponseisalsounknownyet.Then,considering
that TH and RAS inﬂuence several hemodynamic factors
and that the heart is composed by several cell types, which
could be contributing to the participation of the Ang II
receptors in the increase on cardiac TGF-β1 levels, the aim
of the present paper was to investigate whether TH is able
to modulate TGF-β1 levels in isolated cardiac cells, as well
as the possible contribution of AT1R and AT2R in this
process. To address these questions, cardiomyocytes and
cardiac ﬁbroblasts cultures were treated with T3, simulating
a hyperthyroidism condition in vitro. In addition, we used
pharmacologic blockers of AT1R and AT2R to evaluate the
role of these receptors on TGF-β1 levels, as well as in T3-
induced cardiomyocyte hypertrophy.
Herein, we showed that the cardiomyocytes treated with
T3 presented higher TGF-β1 expression levels. In addition,
we conﬁrmed that T3 promotes cardiomyocyte hypertrophy
in part via AT1R and AT2R. However, the T3-induced
increase in TGF-β1 expression in cardiomyocytes was not
changedbytheuseofAT1RandAT2Rblockers.Theseresults
indicate, for the ﬁrst time, that the local Ang II receptors,
present on cardiomyocytes, are not implicated in T3-induced
increase in TGF-β expression in these cells. In addition,
these data suggest that the trophic eﬀects exerted by T3
on cardiomyocytes do not depend on the higher TGF-β1
levels, as observed previously for us in vivo, since the AT1R
and AT2R blockers were able to attenuate the T3-induced
cardiomyocyte hypertrophy but were not able to modulate
the increase in TGF-β1l e v e l sp r o m o t e db yT 3 in these
cells.
2.MaterialandMethods
2.1. Cardiac Myocytes and Fibroblasts Cultures. All protocols
were performed in accordance with the Ethical Principles in
Animal Research set forth by the Brazilian College of Animal
Experimentation and were approved by the Biomedical Sci-
ences Institute/USP Ethics Committee for Animal Research.
Primary cultures of neonatal rat ventricular cardiomyocytes
were prepared by enzymatic disaggregation, as described
previously by us in [20]. To segregate myocytes from
nonmyocytes, the dissociated cells were layered into dis-
continuous Percoll (Amersham Biosciences, Sweden) density
gradient. The cells were collected and washed to remove all
traces of Percoll. Cellular viability was estimated by Trypan
blue method. Cardiomyocytes were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, GIBCO) containing 5%
newborn calf serum (NCS; Invitrogen, Carlsbad, CA) and
10% horse serum (Invitrogen). The cardiac ﬁbroblasts were
cultured in DMEM containing 10% fetal bovine serum
(Invitrogen), which in conﬂuence, were submitted subse-
quently to subculture. Cells from passage 1 through 2 were
grown to conﬂuence and then used in the experiments. The
cells were maintained in a humidiﬁed incubator (5% CO2,
37
◦C).
2.2. Treatment of the Cells. 72 hours after plating, the
isolated cardiac cells were maintained in DMEM containing
serum 0.5% for 24 hours. Then, the cardiomyocytes and
cardiac ﬁbroblasts cultures were treated with serum-free
medium containing T3 (10nM, Sigma, St. Louis, MO)
or only serum-free medium in control cells for 24 hours.
To evaluate the possible role of AT1R and AT2R on
cardiomyocytes cultures, the cells were treated with serum-
free medium containing T3 (10nM), T3 plus Losartan (Los,
1μM,SigmaChemical),T3 plusPD123319(PD,1μM,Sigma
Chemical) or only serum-free medium in control cells for
24 hours.
2.3. Protein Synthesis. Protein synthesis on cardiomyocytes
cultureswasquantiﬁedonthebasisoftritiatedleucineincor-
poration[21]. Six hours before harvest, L-[3,4,5-3H] leucine
(5μCi/ml) was added to the culture medium to measure
incorporation into newly synthesized protein. Total cellular
proteins were precipitated in ice-cold 10% trichloroacetic
acid and collected by centrifugation (14000Xg, 10min,
4◦C).Theproteinspelletswerewashedtwicebyresuspension
in cold 10% trichloroacetic acid and collected by centrifu-
gation. The ﬁnal pellets were dissolved in 0.2N NaOH
by incubation at 60
◦C for 30min. The radioactivity was
measured by liquid scintillation counting and normalized by
the total cell number.
2.4. Western Blotting. Protein expression of TGF-β1a n dα-
actinin was determined by Western Blotting experiments.
Total proteins from cell cultures were obtained using diges-
tionbuﬀer(KCl90mM,Hepes10mM,MgCl
2+ 3mM,EDT A
5mM, glycerol 1%, DTT 1mM, SDS 0.04%). Protein con-
centrationswereanalyzedbytheBradfordmethod(Bradford
1976). One hundred μg of total protein was resolved by
electrophoresis on 5% stacking/10% polyacrylamide-SDS
gels, and the resolved proteins were transferred to nitro-
cellulose membrane (Bio-Rad, CA, USA). The membrane
was stained with Ponceau solution to demonstrate that the
protein concentration was similar in the diﬀerent samples.
The membrane was then washed with TBST (Tris 50mM,
NaCl 150mM, pH7.5 and Tween-20 2%) for 10minutes at
room temperature. After this, the membrane was incubated
at 4◦C overnight with polyclonal antibody against TGF-β1
(Santa Cruz Biotechnology, CA, USA, SC-146, 1:500) and
α-actinin (Santa Cruz Biotechnology, SC-15335, 1:1000) inInternational Journal of Endocrinology 3
TBST.Afterwashingthemembrane,thesecondaryantirabbit
orantigoatIgGantibodyconjugatedwithperoxidase(Amer-
sham Biosciences, New Jersey, USA) at a 1:10000 dilution
in TBST was added for 1 hour at room temperature. The
membrane was washed again with TBST and was incubated
withECL detection reagents(AmershamBiosciences), which
produced a chemiluminescence signal that was detected by
exposure to X-ray ﬁlm. The protein bands were quantiﬁed
by densitometry and the band density was then calculated.
The TGF-β1 protein expression was normalized by α-actinin
expression.Thevaluesareexpressedinpercentageinrelation
to control.
2.5. Gene Expression Analysis. Total RNA from cardiomy-
ocytes and ﬁbroblasts cultures were isolated with Trizol
Reagent (Invitrogen, CA, USA) in accordance with the man-
ufacturer’s instructions. The cDNA species were synthesised
with SuperScript II (Life Technologies) from 2μgo ft o t a l
RNA in a total volume of 20μL with an oligo (dT) primer.
The cDNA reactions were performed for 1 hour at 42
◦C
and stopped by boiling for 5minutes. The cDNA was used
as a template for PCR with speciﬁc primers for TGF-β1. A
210-bp sequence of the β-actin mRNA was chosen as an
internal standard RNA for PCRs. To ensure that we were
workinginconditionsofnonsaturationforthePCRreaction,
a cycle curve was ﬁrst made for each gene, since this is a
semiquantitative method. Two microlitres of the RT reaction
mix were used for PCR in a total volume of 25μl using
the concentration of 0.5μM of each primer indicated below,
together with 50μMo fd N T Pa n d1 Uo fT a qp o l y m e r a s e
(Life Technologies) in the supplied reaction buﬀer. The
primer of β-actin used in the reaction was diluted (1:20).
The PCR cycling conditions were as follows: for TGF-β1:
1minuteat94
◦C, 1minute at 64
◦C, and 1 minute at 72
◦C
(498-bp ampliﬁcation product in 21cycles); and for β-actin:
1minute at 94
◦C, 1.5minute at 59.8
◦C, and 1minute 30s
at 72
◦C (210-bp ampliﬁcation product in 34 cycles). All
PCRs were carried out for an initial 3-minutes denaturation
step at 94
◦C and a ﬁnal 10-minutes extension at 72
◦C. The
following set of primers were used: 5  AAT ACG TCA GAC
ATT CGG GAA GCA 3  and 5  GTC AAT GTA CAG CTG
CCG TAC ACA 3  for TGF-β1; 5 -TAT GCC AAC ACA GTG
CTG TCT GG-3  and 5 -TAC TCC TGC TTC CTG ATC
CACAT-3  forβ-actin.Oligonucleotideswereobtainedfrom
Imprint Genetix (S˜ ao Paulo, Brazil). Ten microlitres of the
PCR product were analyzed on a 1.5% agarose gel. Using an
Image Analysis System, the densitometric intensities of the
TGF-β and β-actin bands were converted to numeric values.
The mRNA expression is expressed as mRNA of the gene
of the interest, and the mRNA/β-actin ratio is expressed as
percentage.
2.6. Statistical Analysis. The data obtained are presented as
mean± SDofatleastthreeindependentexperimentsandare
e x p r e s s e di np e r c e n t a g ei nr e l a t i o nt oc o n t r o l .T h en u m b e r
of experiments (n) refers to the number of diﬀerent cell
extractions and each experiment was performed in triplicate.
Data were analyzed using one-way analysis of variance,
followed by Tukey’s post hoc test, and values of P<. 05 were
considered statistically signiﬁcant.
3. Results
3.1. T3 Increases TGF-β1 Levels in Cardiomyocytes Cultures.
We have previously demonstrated that TH-induced cardiac
hypertrophy was accompanied by elevated cardiac TGF-
β1 protein expression [19]. In order to evaluate whether
TH would be able to modulate directly TGF-β1 in isolated
cardiac cells, we analyzed its protein and gene expression in
cardiomyocytes cultures and in cardiac ﬁbroblasts cultures,
using, respectively, western Blotting and RT-PCR analysis
(Figure 1). The cardiac ﬁbroblasts submitted to T3 (10nM)
treatment for 24 hours did not present alteration on TGF-
β1 protein and gene expression compared to control cells
(Figures1(a)and 1(c)).However,thecardiomyocytestreated
with T3 (10nM) for 24 hours demonstrated a signiﬁcant
increase on TGF-β1 protein and gene expression (P<. 01)
in relation to control cells (Figures 1(b) and 1(d)).
These results demonstrate that T3 increases the TGF-β1
protein and gene expression in cardiomyocytes cultures.
3.2. T3 Induces Cardiomyocyte Growth via AT1R and AT2R.
We have previously demonstrated that AT1R acts as key
mediator in the TH-mediated cardiac hypertrophy in vivo
[9] and in vitro [11]. In addition, the AT2R was also
shown to participate in this cardiac hypertrophy model.
To conﬁrm the participation of AT1R and AT2R in T3-
inducedcardiomyocytehypertrophy,weanalyzedtheprotein
synthesis as an indicator of hypertrophy (Figure 2). To
address these questions, the cells were treated with T3
(10nM), T3 plus Losartan (1μM), an AT1R blocker, or
T3 plus PD123319 (1μM), an AT2R blocker. As expected,
the cardiomyocytes treated with T3 for 24 hours presented
a signiﬁcant increase in protein synthesis (P<. 01) in
relation to control cells. However, protein synthesis was
signiﬁcantly lower in the cardiomyocytes treated with T3
plus Losartan (P<. 01) than in those only treated with T3.
Similar results were obtained from the cells treated with T3
plus PD123319, which demonstrated a signiﬁcant reduction
on protein synthesis (P<. 05) when compared to T3 -
treated cells. However, the cardiomyocytes treated with T3
plus PD123319 presented a signiﬁcant increase on protein
synthesis (P<. 05) in relation to control cells.
These data conﬁrm the hypertrophic eﬀect exerted by T3
on cardiomyocytes, as well as the important contribution of
AT1R and AT2R in this process.
3.3. T3 Increases TGF-β1 in Cardiomyocytes Independent of
AT1R and AT2R. We have previously showed that TH-
induced cardiac hypertrophy in vivo is accompanied by
increased cardiac TGF-β1 levels, which is mediated by AT1R
and AT2R [19]. To investigate whether the T3-induced
increase on TGF-β1 expression in cardiomyocytes cultures
might be mediated by the local Ang II receptors, present in
these cells, as well as the possible participation of the TGF-
β1 to the trophic eﬀects exerted by T3 on cardiomyocytes,4 International Journal of Endocrinology
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Figure 1: TGF-β1 protein expression in cardiac ﬁbroblasts (a) and cardiomyocytes cultures (b), evaluated by Western Blot. TGF-β1g e n e
expression in cardiac ﬁbroblasts (c) and cardiomyocytes cultures (d), evaluated by RT-PCR. The cells were treated for 24 hours with serum-
free medium containing 10nM of T3 (T3) or only serum-free medium in control cells. α-actinin was used for normalization of TGF-β1
protein expression and β-actin was used for normalization of TGF-β1 gene expression. The values are expressed in percentage. ∗versus
control P<. 01 (n = 4).
we also evaluated the participation of AT1R and AT2R in
theT3-inducedincreaseonTGF-β1expression,usingspeciﬁc
blockers(Figure3).Thecardiomyocytesculturestreatedwith
T3 (10nM) plus Losartan (1μM) demonstrated a signiﬁcant
increase in TGF-β1 expression (P<. 01) in relation to
control values. In the same way, the cardiomyocytes cultures
treated with T3 (10nM) plus PD123319 (1μM) presented
higher TGF-β1 expression (P<. 01) compared to control
cells.
These results demonstrate that AT1R and AT2R do not
mediate the T3-induced increase in TGF-β1p r o t e i ne x -
pression in cardiomyocytes cultures.
4. Discussion
Alterations on TH levels are able to inﬂuence cardiac
function in diﬀerent routes [22]. In this context, increased
TH levels have been shown to promote cardiac hypertrophy
[23] and Ang II receptors have a key role in mediating
this process [9, 11]. In addition, TH levels have also been
shown to inﬂuence the cardiac Ang II receptors expression
[24]. We have previously described that TH-induced cardiac
hypertrophy is accompanied by elevated cardiac TGF-β1
levels [19]. However, the exact mechanism by which TH
increases the cardiac TGF-β1 levels is unknown. ConsideringInternational Journal of Endocrinology 5
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Figure 2:
3H-Leucine incorporation in cells treated with serum-
free medium containing 10nM of T3 (T3), as well as in cells
treated with 10nM of T3 plus 1μMo fL o s a r t a n( L o s+T 3), 10nM
of T3 plus 1μM of PD123319 (PD + T3) for 24 hours or only
serum-free medium in control cells. Six hours before harvest, L
[3,4,5-3H]leucine (5μCi/ml) was added to the culture medium to
measure incorporation into newly synthesized protein. Results are
expressed as percentages. ∗P<. 01 versus control, ∗∗P<. 05 versus
control, #P<. 01 versus T3,# # P<. 05 versus T3 (n = 3).
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Figure 3: TGF-β1 protein expression in cardiomyocytes cultures
evaluated by Western Blot in cells treated with serum-free medium
containing 10nM of T3 (T3), as well as in cells treated with 10nM
of T3 plus 1μMo fL o s a r t a n( L o s+T 3), 10nM of T3 plus 1μM
of PD123319 (PD + T3) for 24 hours or only serum-free medium
in control cells. α-actinin was used for normalization of TGF-β1
expression. The values are expressed in percentage.∗versus control
P<. 01 (n = 3).
this, the present was designed to evaluate whether TH would
be able to modulate directly TGF-β1 expression in isolated
cardiac cells, as well as the possible contribution of AT1R
and AT2R to this response. Our results demonstrated that T3
induces an increase in TGF-β1 protein and gene expression
in cardiomyocytes cultures but does not change the TGF-β1
protein and gene expression in cardiac ﬁbroblasts cultures.
In order to conﬁrm the critical role exerted by the Ang
II receptors to the development of T3-induced cardiomy-
ocyte hypertrophy, we evaluated the protein synthesis of
cardiomyocytes treated with T3 p l u sA T 1 Rb l o c k e ro rT 3 plus
AT2R blocker. Herein, we conﬁrmed again that T3 stimulates
cardiomyocyte hypertrophy via AT1R, since the use of a
pharmacologic blocker of this receptor totally prevented
the T3-induced cardiomyocyte hypertrophy. In addition,
our results demonstrated that AT2R also contributes to the
development of cardiomyocyte growth promoted by T3,
since the use of a pharmacologic blocker of this receptor
minimized the T3-induced hypertrophy. This result is in
agreement with some recent studies of the literature, which
have implicated the AT2R as a mediator of cardiac growth
in vivo and in vitro [13, 14]. However, the participation of
AT1R to the T3-induced cardiomyocyte growth seems to be
more accentuated than the participation of AT2R, suggesting
that the AT1R is the main receptor responsible to mediate
the trophic eﬀects exerted by Ang II in these cells submitted
to T3 treatment.Thisisanimportant question,whichshould
be investigated.
We have previously demonstrated that the Ang II recep-
tors mediate the increase in cardiac TGF-β1 levels during the
TH-induced cardiac hypertrophy in vivo [19]. Considering
that TH and RAS inﬂuence several hemodynamic factors,
which could be responsible for the participation of the
Ang II receptors in the TH-induced increase on cardiac
TGF-β1 levels, in this study we evaluated whether the T3-
induced increase in TGF-β1 expression in cardiomyocytes
cultures might be mediated by the local Ang II receptors
present in these cells. Herein, we demonstrated that the
increase induced by T3 on TGF-β1 protein expression in
cardiomyocytes cultures is not mediated by the Ang II
receptors, since the use of AT1R and AT2R blockers did
not attenuate the increase on TGF-β1 protein expression
promoted by T3 in these cells. These data suggest that the
participation of the Ang II receptors mediating the increase
on TGF-β1 protein expression in the TH-induced cardiac
hypertrophy in vivo probably is not dependent on the local
AT1R and AT2R present in the cardiomyocytes. Moreover,
considering that the AT1R and AT2R blockers prevented
the increase in systolic blood pressure promoted by TH in
vivo, as well as the increase in cardiac TGF-β1l e v e l s[ 19],
it is plausible that the hemodynamic parameters altered in
TH-induced cardiac hypertrophy may be inﬂuencing the
elevated TGF-β1 levels in this model. In addition, several
recent studies have emphasized the complexity of cardiac
intracellular interactions where heart cells may be both
source and target of signals such as cytokines and growth
factors [25–27]. In this sense, the preservation of the cardiac
architecture in vivo may be critical to the elevated cardiac
levels of TGF-β1 promoted by TH mediated by Ang II
receptors.
Studies using cardiomyocytes cultures indicate that TGF-
β1 stimulates protein synthesis [28]. In addition, the causal
link between Ang II and TGF-β1 in cardiac hypertrophy
was recently demonstrated [29], since TGF-β1 expression is
increased by Ang II in cardiomyocyte [30]. In this sense,
the myocardial induction of TGF-β1h a sb e e nf o c u so f6 International Journal of Endocrinology
particular interest in cardiac biology because this cytokine
plays a crucial role in the transition from compensated to de-
compensated hypertrophy [31]. Taking this into account, it
would be possible to suppose that part of the hypertrophic
eﬀect exerted by T3 on cardiomyocytes might be mediated
by the higher TGF-β1 protein expression. However, our
data suggest that the trophic eﬀects exerted by T3 on
cardiomyocytes are not dependent of the higher TGF-β1
levels, since the AT1R and AT2R blockers were able to
attenuate the T3-induced cardiomyocyte hypertrophy but
were not able to attenuate the increase on TGF-β1l e v e l s
promoted by T3 in these cells. However, considering that
the eﬀects of TGF-β1 are mediated by TGFR-β1 and TGFR-
β2 receptors, which are present in cardiomyocytes [32], the
existence of the possible action of TH on TGF-β1r e c e p t o r s
have to be considered. In this sense, it would be important
to evaluate the TH eﬀect on TGF-β1 receptors in isolated
cardiomyocytes. However, future studies will help in the
elucidation of the exact role exerted by the elevated TGF-β1
expression in T3-treated cardiomyocytes.
5. Conclusions
In summary, the data obtained in the present study demon-
strate for the ﬁrst time that T3 increases TGF-β1p r o t e i n
and gene expression in cardiomyocytes cultures. In addition,
the results evidenced that the TH-induced increase on
TGF-β1 levels in cardiomyocytes cultures is not dependent
on local AT1R and AT2R present in these cells. Finally,
these data suggest that the trophic eﬀects exerted by T3
on cardiomyocytes are not dependent on the higher TGF-
β1 levels, since the AT1R and AT2R blockers were able to
attenuate the T3-induced cardiomyocyte hypertrophy but
were not able to attenuate the increase on TGF-β1l e v e l s
promoted by T3 in these cells.
Acknowledgments
This paper received ﬁnancial support from the Fundac ¸˜ ao
de Amparo ` a Pesquisa do Estado de S˜ ao Paulo (FAPESP)
and the Conselho Nacional de Desenvolvimento Cient´ ıﬁco
eT e c n o l ´ ogico (CNPq, National Council for Scientiﬁc and
Technological Development).
References
[1] S. Gupta, B. Das, and S. Sen, “Cardiac hypertrophy: mecha-
nisms and therapeutic opportunities,” Antioxidants and Redox
Signaling, vol. 9, no. 6, pp. 623–652, 2007.
[2] P. Lijnen and V. Petrov, “Renin-angiotensin system, hyper-
trophy and gene expression in cardiac myocytes,” Journal of
Molecular and Cellular Cardiology, vol. 31, no. 5, pp. 949–970,
1999.
[3] M. Harada, H. Itoh, O. Nakagawa, et al., “Signiﬁcance of
ventricularmyocytesandnonmyocytesinteractionduringcar-
diocyte hypertrophy: evidence for endothelin-1 as a paracrine
hypertrophic factor from cardiac nonmyocytes,” Circulation,
vol. 96, no. 10, pp. 3737–3744, 1997.
[4] M. Harada, Y. Saito, K. Kuwahara, et al., “Interaction of
myocytesandnonmyocytesisnecessaryformechanicalstretch
toinduceANP/BNPproductionincardiocyteculture,”Journal
of Cardiovascular Pharmacology, vol. 31, no. 1, pp. S357–S359,
1998.
[5] P. L. Puri, G. Natoli, M. L. Avantaggiati, C. Balsano, P. De
Marzio, and M. Levrero, “The molecular basis of myocardial
hypertrophy,” Annali Italiani di Medicina Interna, vol. 9, no. 3,
pp. 160–165, 1994.
[ 6 ]A .J .E .T .V a nW a m e l ,C .R u w h o f ,L .E .V a nD e rV a l k -
Kokshoorn, P. I. Schriern, and A. Van Der Laarse, “The
role of angiotensin II, endothelin-1 and transforming growth
factor-β as autocrine/paracrine mediators of stretch-induced
cardiomyocyte hypertrophy,” Molecular and Cellular Biochem-
istry, vol. 218, no. 1-2, pp. 113–124, 2001.
[ 7 ]U .M .S c h m i d t - O t ta n dD .D .A s c h e i m ,“ T h y r o i dh o r m o n e
and heart failure,” Current Heart Failure Reports, vol. 3, no. 3,
pp. 114–119, 2006.
[8] F.Liang,P.Webb,A.Marimuthu,S.Zhang,andD.G.Gardner,
“Triiodothyronine increases brain natriuretic peptide (BNP)
gene transcription and ampliﬁes endothelin-dependent BNP
genetranscriptionandhypertrophyinneonatalratventricular
myocytes,” Journal of Biological Chemistry, vol. 278, no. 17, pp.
15073–15083, 2003.
[9] L.W.Hu,L.A.Benvenuti,E.A.Liberti,M.S.Carneiro-Ramos,
and M. L. M. Barreto-Chaves, “Thyroxine-induced cardiac
hypertrophy: inﬂuence of adrenergic nervous system versus
renin-angiotensin system on myocyte remodeling,” American
Journal of Physiology, vol. 285, no. 6, pp. R1473–R1480, 2003.
[10] C. Pantos, I. Paizis, I. Mourouzis, et al., “Blockade of
angiotensin II type 1 receptor diminishes cardiac hypertrophy,
but does not abolish thyroxin-induced preconditioning,”
Hormone and Metabolic Research, vol. 37, no. 8, pp. 500–504,
2005.
[11] G. P. Diniz, M. S. Carneiro-Ramos, and M. L. Barreto-Chaves,
“Angiotensin type 1 receptor mediates thyroid hormone-
induced cardiomyocyte hypertrophy through the Akt/GSK-
3β/mTOR signaling pathway,” Basic Research in Cardiology,
vol. 104, no. 6, pp. 653–667, 2009.
[12] J. Varagic and E. D. Frohlich, “Local cardiac renin—
angiotensin system: hypertension and cardiac failure,” Journal
of Molecular and Cellular Cardiology, vol. 34, no. 11, pp. 1435–
1442, 2002.
[13] A. D’Amore, M. J. Black, and W. G. Thomas, “The angiotensin
II type 2 receptor causes constitutive growth of cardiomy-
ocytes and does not antagonize angiotensin II type 1 receptor-
mediated hypertrophy,” Hypertension, vol. 46, no. 6, pp. 1347–
1354, 2005.
[14] T. Senbonmatsu, S. Ichihara, E. Price Jr., F. A. Gaﬀney, and
T. Inagami, “Evidence for angiotensin II type 2 receptor-
mediated cardiac myocyte enlargement during in vivo pres-
sure overload,” Journal of Clinical Investigation, vol. 106, no. 3,
pp. R25–R29, 2000.
[15] J. N. Cohn, R. Ferrari, and N. Sharpe, “Cardiac remodeling-
concepts and clinical implications: a consensus paper from an
International Forum on Cardiac Remodeling,” Journal of the
American College of Cardiology, vol. 35, no. 3, pp. 569–582,
2000.
[16] J. M. Schnee and W. A. Hsueh, “Angiotensin II, adhesion, and
cardiac ﬁbrosis,” Cardiovascular Research, vol. 46, no. 2, pp.
264–268, 2000.
[17] F. J. Villarreal and W. H. Dillmann, “Cardiac hypertrophy-
induced changes in mRNA levels for TGF-β1, ﬁbronectin, andInternational Journal of Endocrinology 7
collagen,” AmericanJournalofPhysiology,vol.262,pp.H1861–
H1866, 1992.
[18] H. Lim and Y. Z. Zhu, “Role of transforming growth factor-β
in the progression of heart failure,” Cellular and Molecular Life
Sciences, vol. 63, no. 22, pp. 2584–2596, 2006.
[19] G. P. Diniz, M. S. Carneiro-Ramos, and M. L. M. Barreto-
Chaves, “Angiotensin type 1 (AT1) and type 2 (AT2) receptors
mediate the increase in TGF-β1 in thyroid hormone-induced
cardiac hypertrophy,” Pﬂ¨ ugers Archiv European Journal of
Physiology, vol. 454, no. 1, pp. 75–81, 2007.
[ 2 0 ]M .L .M .B a r r e t o - C h a v e s ,A .H e i m a n n ,a n dJ .E .K r i e g e r ,
“Stimulatory eﬀect of dexamethasone on angiotensin-
converting enzyme in neonatal rat cardiac myocytes,”
Brazilian Journal of Medical and Biological Research, vol. 33,
no. 6, pp. 661–664, 2000.
[21] A. Kenessey and K. Ojamaa, “Thyroid hormone stimulates
protein synthesis in the cardiomyocyte by activating the Akt-
mTORandp70S6K pathways,”JournalofBiologicalChemistry,
vol. 281, no. 30, pp. 20666–20672, 2006.
[22] G. J. Kahaly and W. H. Dillmann, “Thyroid hormone action
in the heart,” Endocrine Reviews, vol. 26, no. 5, pp. 704–728,
2005.
[23] B. M. Fadel, S. Ellahham, M. D. Ringel, J. Lindsay Jr., L.
Wartofsky, and K. D. Burman, “Hyperthyroid heart disease,”
Clinical Cardiology, vol. 23, no. 6, pp. 402–408, 2000.
[24] M. S. Carneiro-Ramos, G. P. Diniz, J. Almeida, et al., “Cardiac
angiotensin II type I and type II receptors are increased in
rats submitted to experimental hypothyroidism,” Journal of
Physiology, vol. 583, no. 1, pp. 213–223, 2007.
[25] S. Fredj, J. Bescond, C. Louault, and D. Potreau, “Interactions
between cardiac cells enhance cardiomyocyte hypertrophy
and increase ﬁbroblast proliferation,” Journal of Cellular
Physiology, vol. 202, no. 3, pp. 891–899, 2005.
[26] S. Fredj, J. Bescond, C. Louault, A. Delwail, J.-C. Lecron, and
D. Potreau, “Role of interleukin-6 in cardiomyocyte/cardiac
ﬁbroblast interactions during myocyte hypertrophy and
ﬁbroblast proliferation,” Journal of Cellular Physiology, vol.
204, no. 2, pp. 428–436, 2005.
[27] M. L. M. Barreto-Chaves, I. Aneas, and J. E. Krieger, “Glu-
cocorticoid regulation of angiotensin-converting enzyme in
primary culture of adult cardiac ﬁbroblasts,” American Journal
of Physiology, vol. 280, no. 1, pp. R25–R32, 2001.
[28] J. R. Florini and D. Z. Ewton, “Actions of anabolic hormones
and growth factors on cultured neonatal heart cells,” Growth
Regulation, vol. 5, no. 1, pp. 28–35, 1995.
[29] J. Schultz Jel, S. A. Witt, B. J. Glascock, et al., “TGF-beta1
mediates the hypertrophic cardiomyocyte growth induced by
angiotensin II,” Journal of Clinical Investigation, vol. 109, pp.
787–796, 2002.
[30] M. O. Gray, C. S. Long, J. E. Kalinyak, H.-T. Li, and
J. S. Karliner, “Angiotensin II stimulates cardiac myocyte
hypertrophy via paracrine release of TGF-β1 and endothelin-
1 from ﬁbroblasts,” Cardiovascular Research,v o l .4 0 ,n o .2 ,p p .
352–363, 1998.
[31] S. Wenzel, K. Schorr, H. Degenhardt, et al., “TGF-β(1)
downregulates PTHrP in coronary endothelial cells,” Journal
of Molecular and Cellular Cardiology, vol. 33, no. 6, pp. 1181–
1190, 2001.
[32] T. Brand and M. D. Schneider, “Inactive type II and type
Ir e c e p t o r sf o rT G F β are dominant inhibitors of TGFβ-
dependent transcription,” Journal of Biological Chemistry, vol.
270, no. 14, pp. 8274–8284, 1995.